Fig. 5: MCL-1 inhibition with S63845 reinvigorates TME towards immunogenicity in a syngeneic MYC-driven lymphoma mouse model.
From: Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma
A Representative flow cytometry dot plot (left) and quantification (right) showing a reduction in tumor B cells among CD45+ cells following S63845 treatment. B Increased proportions of CD3+ T cells among viable lymphocytes, and CD4+ and CD8+ T cells among CD45+ cells after S63845 treatment measured by flow cytometry. C Decreased proportions of PD-1+, Tim-3+, and CD25+ cells among CD4+ T cells, as well as GR-1+ CD11b+ myeloid cells among CD45+ cells following S63845 treatment, measured by flow cytometry.
